+44 (0) 1698 534002
Contact

News

BioAscent Enhances Capabilities with New Flow Cytometer

09 May 2025

BioAscent is pleased to announce the recent investment in a new NovoCyte 3000 flow cytometer, a cutting-edge piece of eq...

Read more

BioAscent appoints James Hitchin as Vice President of Alliance Management

05 May 2025

BioAscent is pleased to announce the appointment of life sciences executive leader, James Hitchin, as Vice President of...

Read more

BioAscent invests in Seahorse XF Pro Analyser Platform

17 March 2025

BioAscent’s latest investment in a state-of-the-art Seahorse XF Pro Analyser Platform has strengthened the company’s mit...

Read more

BioAscent significantly outperforms market despite challenging marketing conditions

25 February 2025

“Green shoots” show signs of recovery in the sector, with BioAscent winning a number of new contracts.BioAscent has repo...

Read more

Meet the Team: Michael Mathieson, Senior Scientist - Chemistry

16 December 2024

In our latest Meet the Team blog, we asked Michael Mathieson about his career journey, from what inspired him to get int...

Read more

From placement to permanent: BioAscent welcomes Rita Pereira to the biosciences team

10 December 2024

BioAscent is pleased to welcome Rita Pereira back to the company as a permanent member of the biosciences team, followin...

Read more

BioAscent's leading expertise in GPCR drug discovery drives customer success

26 November 2024

We never set out to become a specialist GPCR drug discovery company, nor do we see ourselves as one today. Our identity...

Read more

BioAscent awarded prestigious Knowledge Transfer Partnership with Centre for Targeted Protein Degradation at the University of Dundee

04 November 2024

New collaboration to develop innovative chemistry for more efficient protein degrader molecules.BioAscent is proud to an...

Read more

BioAscent welcomes back Nikita Shvedov

16 October 2024

This summer Nikita Shvedov returned to BioAscent to take up a permanent position in the Biosciences team as an Associate...

Read more

COLLABORATION BETWEEN ARKUDA THERAPEUTICS AND BIOASCENT IDENTIFIES NOVEL TRPML1 AGONISTS

27 September 2024

The team at Arkuda Therapeutics, a leading US-based biotechnology company, joined forces with BioAscent to discover nove...

Read more

Integrated Drug Discovery

Science-led drug discovery

Compound Management

Connecting and accelerating your drug discovery

Medicinal Chemistry

Proven expertise in design and synthesis

In Silico Discovery

Accelerating drug design with computational expertise

Discovery Biology

Screening expertise across target classes

Get in Touch

Let's talk about how we can maximise your drug discovery success.

Contact